Global Chronic Urticaria Or Hives Drug Market Size By Type (GDC-0853, GSK-2646264), By Application (Clinic, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Chronic Urticaria or Hives Drug Market was valued at USD 3.4 billion in 2023 and is projected to reach USD 6.1 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2023–2031). The growth of this market is driven by the increasing prevalence of chronic urticaria globally, growing awareness of skin-related disorders, and advancements in drug therapies, especially biologics and antihistamines. Rising healthcare expenditure, improved diagnostics, and the expanding geriatric population susceptible to autoimmune diseases are also propelling the market forward.

Drivers:

1. Rising Prevalence of Chronic Urticaria:

The increasing incidence of chronic urticaria, particularly among adults and the aging population, is a major growth driver. Triggers such as autoimmune responses, stress, and allergic reactions are escalating the demand for effective treatments.

2. Advancements in Biologic Therapies:

The introduction and FDA approval of biologics like omalizumab have significantly enhanced treatment efficacy, particularly for patients resistant to antihistamines. Continuous R&D in targeted therapies is fueling innovation.

3. Growing Awareness and Dermatological Consultations:

Public health campaigns, patient advocacy groups, and better access to dermatologists have increased early diagnosis and treatment uptake, thus expanding the consumer base for chronic urticaria drugs.

Restraints:

1. High Cost of Biologics:

Although biologics are highly effective, their high costs and limited accessibility in developing regions can hinder market growth. Insurance coverage limitations also remain a challenge.

2. Adverse Effects and Drug Resistance:

Prolonged use of antihistamines and corticosteroids can lead to side effects or resistance, necessitating careful medical oversight, which may affect long-term patient adherence.

Opportunity:

1. Untapped Markets in Emerging Economies:

Regions such as Latin America, Southeast Asia, and parts of Africa present high growth potential due to rising healthcare investment and growing awareness of chronic skin diseases.

2. Pipeline Expansion and Drug Innovation:

Strong drug pipelines featuring next-generation antihistamines and IL-targeting biologics create new avenues for pharmaceutical companies to differentiate and capture market share.

Market by System Type Insights:

The Antihistamines segment accounted for the largest market share in 2023, driven by their status as first-line treatment and over-the-counter availability. However, the Biologics segment is expected to witness the fastest growth during the forecast period due to higher efficacy in refractory cases and increasing physician preference for targeted treatments.

Market by End-use Insights:

The Hospitals and Specialty Clinics segment held the largest market share in 2023. These facilities are equipped for administering advanced biologics and handling complex cases. Meanwhile, Retail Pharmacies are projected to grow steadily due to easy access to non-prescription antihistamines and follow-up prescriptions.

Market by Regional Insights:

North America led the global market in 2023, owing to high healthcare spending, early adoption of novel therapies, and a well-established pharmaceutical industry. Asia-Pacific is forecasted to experience the highest growth rate, supported by a growing patient population, healthcare infrastructure upgrades, and increased awareness of skin diseases.

Competitive Scenario:

Key players in the Global Chronic Urticaria or Hives Drug Market include:

Novartis AG

Sanofi S.A.

Pfizer Inc.

Bayer AG

Teva Pharmaceutical Industries Ltd.

Genentech (Roche)

Johnson & Johnson

UCB Pharma

GlaxoSmithKline plc

AbbVie Inc.

These companies are focusing on expanding their product portfolios, gaining regulatory approvals, and forming strategic partnerships. For instance:

In 2023, Novartis launched a follow-up study for Xolair (omalizumab) to expand indications in chronic spontaneous urticaria (CSU).

In 2024, Sanofi and Regeneron initiated Phase III trials for dupilumab in urticaria treatment beyond atopic dermatitis.

Pfizer announced in 2025 a licensing agreement for a novel oral histamine receptor antagonist showing promise in late-stage trials.

Scope of Work – Global Chronic Urticaria or Hives Drug Market

Key Market Developments:

2023: FDA approved expanded indications for omalizumab in pediatric CSU.

2024: Sanofi announced a global licensing agreement with a biotech startup for IL-31 targeting urticaria treatment.

2025: Johnson & Johnson introduced a topical antihistamine formulation aimed at mild to moderate hives with fewer side effects.

FAQs:

1. What is the current market size of the Global Chronic Urticaria or Hives Drug Market?

The market was valued at USD 3.4 billion in 2023.

2. What is the major growth driver of the Global Chronic Urticaria or Hives Drug Market?

The major driver is the increasing prevalence of chronic urticaria and advancements in biologic treatments.

3. Which is the largest region during the forecast period in the Global Chronic Urticaria or Hives Drug Market?

North America is expected to remain the largest region during the forecast period.

4. Which segment accounted for the largest market share in the Global Chronic Urticaria or Hives Drug Market?

The Antihistamines segment held the largest share in 2023.

5. Who are the key market players in the Global Chronic Urticaria or Hives Drug Market?

Key players include Novartis AG, Sanofi S.A., Pfizer Inc., Bayer AG, and Teva Pharmaceutical Industries Ltd.